RESEARCH / PARTICIPATIONBack to the library
← Find a study
Completed · registry status

A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease

A plain-language introduction is being prepared for this study. Open it to read the original description, who can join and how to contact the team.

Testing a treatment or activity · Study reference: NCT03568968

The registry title is shown while an English plain-language introduction is prepared. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Completed; watching for results

Start (reported actual date)
2020-05-06
Main measurements finished (reported actual date)
2025-06-17
Study finished (reported actual date)
2025-06-17

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — completed

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial.
This paper mentions the study ID; the relationship needs review · 2026

Participation rules recorded for this study

Age 35 years and over · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria: * Have a clinical diagnosis of idiopathic PD according to the MDS clinical diagnostic criteria for Parkinson's disease * \[¹²³I\]FP-CIT single photon emission CT (DaTscan) confirming nigrostriatal degeneration * Diagnosed with PD within 2 years from enrolment * Hoehn and Yahr score \< 3 at enrolment * Optimal symptomatic therapy, not requiring adjustments, for at least 1 month. * Age equal to or greater than 35 years at time of enrolment. Exclusion Criteria: * Dementia or other neurodegenerative disorder at baseline visit * Diagnosed with atypical parkinsonism or vascular parkinsonism * Any psychiatric disorder that would interfere with compliance in the study. * Any severe somatic illness that would make the individual unable to comply and participate in the study. * Use of high dose vitamin B3 supplementation within 30 days of enrolment * Metabolic, neoplastic, or other physically or mentally debilitating disorder at baseline visit. * Genetically confirmed mitochondrial disease
Full study name & original research details

Official study title

A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease: the NOPARK Study

Short title used by the registry

A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease

Original description

NOPARK is a double-blinded randomized controlled phase II trial, with the aim to assess the efficacy of nicotinamide adenine dinucleotide (NAD)-replenishment therapy in the form of oral nicotinamide riboside (NR) in delaying the progression of early Parkinson's disease (PD). A total of 400 persons with early stage Parkinson's disease will be enrolled, randomized on nicotinamide riboside (NR) 500mg x 2 per day or placebo, and followed for 52 weeks.

Further description from the registry

NOPARK is a multi-center, double-blinded randomized controlled trial, with the aim to assess the efficacy of NAD-replenishment therapy in the form of oral nicotinamide riboside (NR) in delaying the progression of early Parkinson's disease (PD). Individuals with PD (n = 400) will be recruited from multiple centers across Norway. Eligible participants must have been diagnosed with PD within 2 years of study enrollment and meet the trial's inclusion criteria. All participants will be given a standard PD-treatment regimen comprising selegiline 10 mg/day and oral levodopa (Sinemet or Madopar) at a dose of 100mg x 3, 150mg x3, or 200mg x 3 per day. The PD-treatment regimen will be frozen at baseline and remain stable throughout the duration of the study. At baseline, participants will be randomized on a 1:1 ratio on either nicotinamide riboside (NR) 500mg x 2 per day or placebo. Both the participants and the investigators will be blinded. The trial duration will be 52 weeks, during which participants will be assessed at baseline, 13, 26, 39 and 52 weeks. Measures include clinical evaluation using established scales for motor and non-motor dysfunction, as well as quality of life, 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane (\[¹²³I\]FP-CIT) single photon emission tomography (DaTscan), magnetic resonance imaging (MRI) of the brain, blood safety tests, and blood sampling for metabolomics, transcriptomics, and other exploratory analyses. The primary outcome of the study is the total score of the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

Conditions reported: Parkinson Disease

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Interventional
Interventions
Nicotinamide Riboside; Placebo
Phases
PHASE3
Sponsor
Haukeland University Hospital
Start date reported by registry
2020-05-06 (actual)

Registry updated: 2025-09-26 · Status last verified by the registry submitter: 2025-09

Registry records retrieved 2026-10-11 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

No central contact is listed. Check the location contacts or the official registry record.

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Bodø Hospital

Bodø, Nordland, Norway

Status not reported

Arendal Hospital

Arendal, Norway

Status not reported

Haukeland University Hospital

Bergen, Norway

Status not reported

Vestre Viken Hospital

Drammen, Norway

Status not reported

Førde sykehus

Førde, Norway

Status not reported

Haugesund Hospital

Haugesund, Norway

Status not reported

Molde sjukehus

Molde, Norway

Status not reported

Akershus university hospital

Oslo, Norway

Status not reported

Oslo University Hospital

Oslo, Norway

Status not reported

University Hospital of North Norway

Tromsø, Norway

Status not reported

Østfold Hospital

Fredrikstad, Østland, Norway

Status not reported

Facility not reported

Norway

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.